• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
Trade NameABBOTT ARCHITECT AFP ASSAY
Classification Namekit, test, alpha-fetoprotein for neural tube defects
ApplicantABBOTT LABORATORIES
PMA NumberP120008
Date Received05/01/2012
Decision Date11/28/2012
Product Code
LOK[ Registered Establishments with LOK ]
Docket Number 12M-1176
Notice Date 12/05/2012
Advisory Committee Immunology
Expedited Review Granted? No
Combination Product No
Information About: Labeling, Approval Order, Summary of Safety and Effectiveness
Approval Order Statement 
Approval for the architect afp assay, architect afp calibrators and architect afp controls. This device is indicated for: the architect afp assay is a chemiluminescent microparticle immunoassay (cmia) for the quantitative determination of alpha-fetoprotein (afp) in:1) human serum or plasma to aid in monitoring disease progression during the course of disease and treatment of patients with nonseminomatous testicular cancer; and 2) human serum, plasma, and amniotic fluid at 15 to 21 weeks gestation to aid in the detection of fetal open neural tube defects (ntd). Test results when used in conjunction with ultrasonography or amniography are a safe and effective aid in the detection of fetal open ntd. The architect afp calibrators are for the calibration of the architect i system when used for the quantitative determination of alpha-fetoprotein (afp) in human serum, plasma, and amniotic fluid. The performance of the architect afp calibrators has not been established with any other afp assays. The architect afp controls are for the estimation of test precision and the detection of systematic analytical deviations of the architect i system when used for the quantitative determination of alpha-fetoprotein (afp) in human serum, plasma, and amniotic fluid. The performance of the architect afp controls has not been established with any other afp assays.
Approval Order Approval Order
Supplements: S001 S002 S003 S004 S005 S006 
-
-